Reinnervate Partners with LGC for Global Distribution of Alvetex®
News Nov 30, 2010
Reinnervate, a life sciences company driving the adoption of routine 3D cell culture, announces that it is partnering with LGC Standards for the non-exclusive distribution and sale of alvetex®, its breakthrough 3D cell culture technology.
LGC Standards is a division of LGC and a supplier of cutting-edge research tools to life science researchers across Europe. The product will be made available for order through the LGC Standards web site www.lgcstandards.com/3D and will also be promoted through a number of LGC Standards product catalogues.
In addition, the companies will be collaborating on the use of alvetex® to generate realistic 3D cell models for drug discovery and development applications. For example, one key area of research has focused on the use of alvetex® to generate liver cell cultures that closely mimic the structure and function of the same cells in the body. An accurate 3D model of the liver can allow researchers to examine the toxicity of new pharmaceuticals and be predictive of the effects of the these drugs in the body, while ultimately reducing the need for animal-based testing.
Data generated by LGC scientists, and funded by the UK’s National Measurement System, demonstrate that liver cells grown in alvetex® produce significantly higher levels of key enzymes involved in drug metabolism and improved responses of the cells to known cytotoxic compounds, than liver cells grown in conventional 2D culture.
Ashley Cooper, CEO of reinnervate, commented: “The partnership with LGC is a significant milestone for the company as we look to launch alvetex® in a range of standard multi-well formats and well inserts over the next 12 months. Alvetex® is a game-changing technology that has the potential to revolutionize the use and value of cell-based applications in basic and industrial research, and as such is in great demand. In order to meet this demand, reinnervate aims to partner, on a non-exclusive basis, with multiple distributors of life sciences research products around the world and is delighted that LGC has become our first partner.”
Jeffrey Anthony, Biologicals Business Unit Manager at LGC Standards commented: “3D cell culture is widely recognized as offering many advantages to cell biologists by enabling cell behavior that more effectively mimics in vivo characteristics. The alvetex® product now makes the benefits of 3D culture routinely available to research laboratories across the world and we are delighted to enable access to this important technology in partnership with the scientists at reinnervate.”
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Big-Data Analysis Points Toward New Drug Discovery MethodNews
A research team has developed a computational method to systematically probe massive amounts of open-access data to discover new ways to use drugs, including some that have already been approved for other uses.
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018